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Purpose: Quantitative study of retinal structure, progression rates and interocular 
symmetry in RPGR-associated retinopathy using spectral domain optical coherence 
tomography (SD-OCT).  
 
Design: Prospective, observational cohort study. 
 
Methods:  
Setting: Moorfields Eye Hospital, London, UK 
Subjects: 38 subjects  
Main outcome measure: Two SD-OCT-derived ellipzoid zone (EZ) metrics with repeatability 
assessments. EZ width (EZW) measurements were made on transfoveal line scans. En face 
images of the EZ area (EZA) were generated from high density macular volume scans and 
quantified. Baseline size, progression rate, symmetry, associations with age and genotype, 
and baseline structure-function correlation were investigated.  
 
Results: Baseline EZW and EZA were 1963.6 µm and 3.70 mm
2
 respectively. Mean EZW 
progression rate was 233.6 µm/year and mean EZA rate was 0.67 mm
2
/year. Relative 
Interocular Difference as an index of symmetry was 3% for both metrics indicating good 
baseline symmetry in general although significant variation existed across the cohort. 
ANOVA results demonstrated a significant effect of age but not genotype on EZ dimension 
and progression rates. Larger EZ dimension and greater progression were seen in younger 
subjects. A positive correlation between EZ dimension and progression was evident. Overall 
exponential decline rates of 8.2% with EZW and 15.5% with EZA were obtained. Good 
functional correlation was found with EZW demonstrating stronger correlation, however 
EZA correlation with function was also signficant. 
 
Conclusions: EZ metrics are sensitive structural biomarkers for measuring residual extent 
and progression in RPGR-associated retinopathy. Our elucidation of the natural history will 
provide clinicians and patients with more knowledge about the condition, and inform the 
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Retinitis pigmentosa (RP) secondary to sequence variants in the retinitis pigmentosa GTPase 
regulator gene (RPGR) constitute around three-quarters of all X-linked (XL) RP 
1-4
, with RP2 
variants predominantly accounting for the remaining cases 
1,3,5-7
. There is particular interest 
in RPGR-associated RP with recently commenced gene therapy trials currently underway 
(NCT03116113, NCT03252847 and NCT03316560). 
 
Spectral-domain optical coherence tomography (SD-OCT) is in widespread use as an imaging 
modality to study retinal structure in a myriad of diseases. Previous OCT studies in RP have 
reported structural changes occurring at the transition zone as the scanned region of 
interest traverses from healthy central retinal tissue to diseased periphery 
8,9
. Structural 
measurements of ellipzoid zone (EZ) width in RP, as a metric of disease severity and 
progression, have been shown to correlate well with retinal function 
10-13
. Serial 
measurements of EZ width (EZW) to assess progression in XLRP have been studied 
14-17
; 
however, these studies were potentially limited by bias in eye selection 
14-16
, do not 
distinguish between genetic causes of XLRP 
14,15
, or are retrospective 
17
. The quantification 
of ellipzoid zone area (EZA), made possible with the use of vendor software to construct en 
face images from SD-OCT volume scans, has been demonstrated to be feasible in 
quantifying progression in autosomal recessive (AR) RP 
18
. Despite this there has not been 
further studies on the use of EZA as a structural metric in RP.  
 
We have therefore investigated the following in this protocol-driven prospective SD-OCT 
study comprising solely of RP subjects with molecularly confirmed pathogenic RPGR 
mutations: (i) intra-observer repeatability with EZW and EZA metrics; (ii) characterize 
baseline retinal structure with both metrics; (iii) characterize progression with both metrics; 
(iv) characterize interocular symmetry at baseline and progression and establish indices to 
quantify symmetry with both metrics; (v) investigate correlations between baseline 
measurements, progression and age; (vi) investigate effects of age and genotype on 
baseline and progression; (vii) determine overall exponential rates of progression with both 
metrics; and (viii) investigate structure-function correlations at baseline with both EZW and 





Approval was granted by the ethics committee at Moorfields Eye Hospital prior to 
conducting the study. The declaration of Helsinki was adhered to throughout. All subjects 
were affected males with RP secondary to molecularly confirmed disease-causing mutations 
in RPGR. Bidirectional sequencing to test for mutations in RPGR exons 1-14 and Open 
Reading Frame 15 (ORF15) was performed at the Central Manchester University Hospitals 
Genomic Diagnostics Laboratory, UK, prior to recruitment. 
 
OCT Acquisition and Analysis 
Dedicated clinical research ophthalmic technicians acquired protocol-driven OCT scans from 
both eyes of each subject at each visit, with the Spectralis OCT device (Heidelberg 














obtained using automated real-time tracking (ART) with an average of 100 images. 
Automatic registration was used for all follow-up scans to ensure accurate correspondence 
of retinal locations. Following line scan acquisition, bilateral macular high-resolution volume 
scans were acquired at the same visit. Each volume scan comprised of 193 horizontal b-
scans in high resolution mode with 30 µm distance between b-scans. Volume scans were 
purposefully acquired to allow the creation of en face images of the ellipzoid zone area 
(EZA). Following a departmental upgrade to the Spectralis OCT imaging platform with OCT2 
module (Heidelberg Engineering, Heidelberg, Germany), volume scans acquired after June 
2016 were captured with an average of 12 images (ART12) per horizontal b-scan, as allowed 
for by increased hardware capabilities and faster scanning speed with significant reduction 
in acquisition time.  
 
Image analyses for both EZW and EZA metrics were performed using vendor software 
(Heidelberg Eye Explorer Version 1.10.2.0). EZW analyses were conducted on transfoveal 
line scan images with the following methodology: Images were displayed in a 1:1 µm 
setting. The nasal and temporal extents of the EZ (point of EZ disappearance into the 
proximal RPE border with loss of outer segment layer) were identified and marked with the 
arrow tool. EZW was measured with the caliper tool as a straight line tangential to the distal 
RPE border (Figure 1). Line scan images were analyzed in a random order for each subject. 
 
En face images of the EZA were created from each macular volume scan with the following 
method using vendor software: Images were created in a 3-dimensional mode and 
displayed in transverse view. The auto-segmented Bruch’s membrane line was manually 
inspected for accurate placement along the outer border of the retinal pigment epithelium-
Bruch’s membrane complex as this line was utilized as a reference for the slab contour. The 
reference line was displaced a distance of 25 µm inwards from Bruch’s membrane and a 
slab of 30 µm thickness was created. Slab settings were designed to capture the whole 
extent of the EZ layer in subjects. Following image creation, the EZA was delineated and 
measured using minimum intensity projection with area value provided by the vendor 
software (Figure 2).  
 
Statistics 
For the assessment of intra-observer repeatability, EZW and EZA baseline images of each 
eye were measured twice by a single observer, a minimum of one week apart. Intra-
observer repeatability assessment was also conducted on EZA derived from ART12 images 
(hereon referred to as EZA-ART12) acquired following upgrade to OCT2. One image per eye 
per subject was used to maintain the “independence-of-score” and to avoid inducing 
systematic bias. The method popularized by Bland and Altman was used to calculate mean ± 
standard deviation (SD) of test-retest differences and corresponding 95% limits of 
agreement (LOA). Residuals were inspected for normality. Repeatability coefficient (RC = 
1.96 *SD) and the test-retest variability for both metrics were calculated and these are 
shown in Table 1.  
 
The Bland Altman method was further utilized to assess interocular symmetry at baseline 
and progression as observed with both metrics (Table 2). An example is provided in Figure 3. 
Baseline EZW and EZA, EZW % rate and EZA % rate residuals were inspected for normality. 














differences were obtained from the subtraction of left from right eyes. Mean of interocular 
differences was expressed as a fraction of its corresponding cohort average [cohort average 
in turn was calculated by obtaining the average of all interocular (mean of right and left eye) 
values of subjects] and this was presented as the Relative Interocular Difference (RID). The 
interocular coefficient (IC = 1.96 *SD), expressed as a fraction of the corresponding cohort 
average was calculated and presented as the Relative Interocular Variability (RIV). These 
indices were calculated to facilitate metric cross-comparison.  
 
Progression rates for individual subjects were calculated by the following method: For each 
eye of each subject, ellipzoid zone measurements obtained with each metric were plotted 
as a function of age on separate scatterplots. As shown in Figure 4, linear trendlines were 
fitted to data points using a least squares method in Microsoft Excel (Mac version 15.41). 
Progression rates for each eye of each subject were obtained from trend line gradients.  
  
Further statistical analyses were performed with XLSTAT version 2018.1 (Addinsoft, New 
York, NY). Data were inspected for normality and log transformation performed prior to 
conducting tests of statistical analyses where required. Interocular correlations at baseline 
and progression were investigated with the Pearson’s correlation coefficient (Table 3). 
Following this, right and left eye data were combined to investigation correlation between 
age and baseline values, age and progression, and correlation between progression and 
baseline values (Table 3).  
 
The effects of age and mutation on baseline and progression were assessed with a two-way 
analysis of variance (ANOVA) as shown in Table 4. Subject age was calculated from birth to 
time at baseline visit and was further divided into five categories: Category 1: <10 years of 
age, Category 2: 10 to <15 years, Category 3: 15 to <20 years, Category 4: 20 to <25 years, 
Category 5: 25 years of age and above. For the assessment of genotype, subjects were 
categorized into groups based on predicted effects of mutations: those will null allele 
mutations (premature stop codons or frameshifts leading to premature stop codons in 
exons 1-14) or those with mutations likely to result in translation of a variant protein 
product (missense mutations and mutations in ORF15). Splice site mutations were 
separately grouped owing to the unpredictability of their effects 
19
. In instances of a 
significant ANOVA result, post-hoc multiple pairwise comparisons were conducted with 
Tukey’s test.  
 
Overall rates of progression for both metrics were modelled using a mixed-models method 
(Table 5). Analysis was performed with age (calculated from birth to time of OCT image 
acquisition) designated as a fixed effects quantitative explanatory variable. Each eye of each 
subject was designated as a random effects variable. Metric values were designated as 
dependent variables. Values were converted into natural log form to model an exponential 
decline. Previous studies have shown progression to be well characterized with an 
exponential decay model 
20-22
, and this is further supported by evidence of exponential 
photoreceptor degeneration in animal models 
23
 and by inspection of our data (Figure 5). 
Distribution of model residuals were inspected for normality. 
 
The association between structure and function was investigated. EZW and EZA data as a 














function performed at the same visit where available. Assessments of best corrected visual 
acuity (BCVA) were conducted with the Early Treatment Diabetic Retinopathy Study chart 
and contrast sensitivity (CS) assessments with the Pelli-Robson chart. BCVA was recorded in 
logarithm of the minimum angle of resolution (logMAR) units and CS as logCS units. 
Automated static perimetry testing was performed on the Octopus 900 (Haag-Streit AG, 
Köniz, Switzerland) using a customized, radially oriented 185-point grid. Perimetry mean 
sensitivity (MS) values in decibel units were obtained from vendor software. The volumetric 
measures of VTotal and V30 in decibel-steradian units were obtained following analysis of 
perimetry data with a third party software (Visual Field Modeling and Analysis software). In 
essence, both VTotal and V30 are metrics that characterize the total amount of sensitivity in 
the hill-of-vision as defined by the entire test grid (VTotal) or that which is contained within a 





Significance level alpha for all statistical tests was set at 0.025 following Bonferroni 





All thirty-eight subjects in this study possessed bilateral ellipzoid zones visible at time of 
baseline imaging. Mean ± SD age for all subjects at baseline was 19.41 ± 8.32 years, ranging 
from 8.37 to 42.12 years. Seventeen subjects possessed mutations in Exon 1-14 and 21 in 
ORF15. Ten were predicted null allele mutations (all harboring Exon1-14 mutations), 25 
predicted variant protein product (of which 4 were Exon 1-14 mutations, and 21 ORF15 
mutations) and 3 splice site mutations.  Bilateral macular OCT volume scans for en face 
analysis were successfully acquired at baseline for a subset of 31 subjects. Mean ± SD age 
for 31 subjects was 20.79 ±8.47, ranging from 8.37 to 42.12 years.  
 
Progression Analysis 
For the calculation of progression rates, linear trend lines were plotted for subjects with 
OCT follow-up spanning a period greater than one year’s duration, with a minimum of three 
imaging visits. 28 subjects had bilateral rates calculated with EZW metric. Mean ± SD follow-
up interval for these 28 subjects was 2.05 ± 0.72 years, ranging from 1.10 to 3.81 years. 21 
subjects had bilateral rates calculated with EZA metric. Mean ± SD follow-up interval for 
these 21 subjects was 2.00 ± 0.74 years, ranging from 1.01 to 3.51 years.  
 
Test-retest Repeatability Analysis  
A comprehensive analysis of intra-observer test-retest repeatability is presented in Table 1. 
For both metrics, the mean of test-retest differences was small in comparison with baseline 
values. For EZW metric, mean test-retest difference was 21.3 µm in comparison to mean 
EZW baseline of 1963.6 µm. Likewise, for EZA metric, mean test-retest difference was 0.025 
mm
2 
in comparison to mean baseline value of 3.70 mm
2
. Calculated 95% LOA lay between -
315.7 µm to 273.1 µm for EZW, between -1.06 mm
2
 to 1.01 mm
2
 for EZA, and between 0.73 
to 0.57 mm
2  
for EZA-ART12. Test-retest variability of 15% for EZW was comparable to test-
















Baseline Values, Progression rates and Assessment of Interocular Symmetry  
Descriptive statistics for baseline values and progression rates are provided in Table 2, 
together with indices of interocular symmetry. One subject (Figure 1) was excluded from 
symmetry analysis as the discrepancy between right and left eye was very large and resulted 
in an outlier effect and not at all in keeping with the entire cohort. Differences in mean EZW 
values at baseline for right eyes (1923.8 µm) and left eyes (2003.4 µm) were statistically 
insignificant (p=0.6750, paired samples t– test). Differences in mean EZA values at baseline 
for right eyes (3.37 mm
2
) and left eyes (4.01 mm
2
) were also statistically insignificant 
(p=0.8177, paired samples t– test).  
 
Interocular differences in progression rates were statistically insignificant as assessed with 
both metrics. Mean EZW rate was 236.82
 
µm/year for right eyes and 230.28 µm/year for left 
eyes (p = 0.9479, paired samples t– test). Mean EZA rate was 0.61 mm
2
/year for right eyes 
and 0.73 mm
2
/year for left eyes (p = 0.3346, paired samples t– test). Equivalent annual 
progression rates in percentage for EZW was 13.6% for right eyes and 12.8% for left eyes. 
Equivalent annual progression rates in percentage for EZA was 16.0% for right eyes and 
17.5% for left eyes.  
  
A very strong interocular correlation at baseline was seen with both EZW and EZA metrics (r 
≥ 0.94, p<0.0001), and for EZA-derived progression (r = 0.93, p<0.0001) as shown in Table 3. 
Interocular correlation for EZW-derived progression was also strong (r = 0.65, p=0.0002), 
albeit of a lesser magnitude in comparison to EZA-derived rates. 
 
Further analysis of interocular symmetry was performed with the Bland-Altman method. 
Results are given in Table 2. A good level of interocular symmetry is evident with the use of 
both metrics to characterize baseline structure. This is reflected in RID values of 3.34% and 
3.07% for EZW and EZA respectively. The RIV, as an index of variability in interocular 
symmetry at baseline, was larger with EZW metrics at 31.87% compared with an RIV of 
17.58% when baseline structure was characterized by the EZA metric.  
 
A greater level of symmetry was seen with the use of EZW over EZA metric when 
characterizing progression. RID for EZW rates was 1.54% compared to 8.93% for EZA. There 
was however greater variability with the use of EZW over EZA. RIV was 102.60% for rates 
defined with EZW compared with 78.01% for rates defined with EZA metric.  
 
Associations of Age, Baseline and Progression  
Correlation data are shown in Table 3. All correlations were statistically significant. A strong 
negative association between age and baseline is evident with both metrics (r= -0.61, p 
<0.0001 for EZW; r= -0.64, p<0.0001 for EZA). A moderate to strong negative correlation 
was seen between age and progression (r = -0.58, p<0.0001 for EZW; r = -0.74, p<0.0001 for 
EZA). A strong positive correlation between baseline and progression was evident with EZA 
(r= 0.83, p<0.0001), with a weaker positive correlation seen with EZW metric (r=0.45, 
p=0.0005).  
 
The effects of age and mutation on baseline values and progression rates were further 














category are shown in Table 4. The effect of age was significant on baseline and progression 
rates as determined by both EZW and EZA metrics. Post-hoc pairwise comparisons revealed 
significant differences between subjects in age categories 1 and 2 versus age categories 4 
and 5. In contrast, the effects of mutation on baseline and progression rates were 
insignificant.  
 
Mixed-Models Analyses to Determine Overall Progression  
Overall rates of progression for the entire cohort was modelled using EZW and EZA data. As 
shown in Table 5, an annual exponential decline rate of 8.22% was obtained with EZW data. 
A greater exponential rate of 15.47% for the cohort was obtained with EZA data. 
 
Associations of Structure and Function  
Correlations between structure and function at baseline are shown in Table 6. All 
correlations were statistically significant. EZW correlated strongly with functional metrics 
VTotal, CS and MS (r = 0.64, 0.64 and 0.63 respectively). The same functional metrics (VTotal, 
CS and MS) also showed greatest correlations with EZA (r = 0.48, 0.60 and 0.45 respectively). 
Correlations between EZW with V30 and BCVA were moderate in strength (r = 0.59 and -0.40 
respectively). Correlations between EZA with V30 and BCVA were weaker, albeit still 





Herein we describe the first protocol-driven SD-OCT study to characterize EZ changes in 
subjects with molecularly proven RPGR-associated RP, using both en face generated EZA 
and transfoveal EZW metrics.  
 
Mean of individual progression rates in our cohort, as calculated by linear trend lines for 
each eye, was 234 µm/year with the EZW metric. This is comparable, albeit slightly less than 





, and 289 µm/year 
16
. Note however that subjects for these three studies 
were obtained from the same source, i.e. the DHA trial (NCT00100230) 
25
 and thus there is 
likely to be a degree of subject overlap in the three studies. Our equivalent mean annual 
progression rate is 13.2% relative to baseline values. This is greater than the annual rate of 
9.6% previously reported in a study with mean baseline EZW of 3410 µm 
16
. On average, 
subjects in our cohort possessed a smaller residual baseline EZ.  
 
With the EZA metric, the mean of individual progression rates in our cohort, as calculated by 
linear trendlines for each eye, was 0.67 mm
2
 /year (16.7%/year). This is comparable to a 
previously reported progression rate of 0.64 mm
2
/year (percentage rate equivalent was not 
provided) 
15
 in a study where the EZA analysis was performed via layer segmentation and 
the use of third party software as acquired volume scans of 31 b-scan density were not 
sufficiently dense to permit the construction of en face images with vendor software.   
 
To our knowledge, the use of en face images to quantify EZA changes in RP has been carried 
out by just one other study, albeit on subjects with ARRP 
18
















/year (13%/year) was reported, however subjects were followed for only one year and 




The other studies on XLRP described above have also calculated progression with data from 
only two time points, taken an average of two years apart. 
15,16
. In these studies, only one 
eye of each subject was chosen for analysis; and in the presence of multiple scans, the one 
with the clearest EZ band was chosen 
16
. Thus, the possibility of selection bias influencing 
results of these studies cannot be excluded.  
 
We have taken a different and arguably more robust approach in our study. Data were 
acquired from both eyes and analyzed separately and then together. Images from multiple 
time points (a minimum of three time points) were analyzed to plot individual trend lines, 
from which progression rates were obtained from the slopes of trend lines. A similar 
approach to calculating progression rates from slopes of linear trend lines has been used by 
Sujirakul and Cabral 
26,27
 in their analyses of EZW, with reported mean progression rate of 
140 µm/year (5.2%/year). Their cohort however comprised RP subjects with various 
inheritances (of which only 5% had XLRP) and thus rates are not directly comparable.   
 
We were able to plot an exponential decline using a mixed-models approach, with data 
taken collectively which afforded a wide age span. Here we found a progression rate of 
8.22% per year with the EZW metric, and 15.47% per year with the EZA metric. Our EZA 
rate, which is roughly twice the EZW progression rate, fulfils the mathematical prediction of 
a doubling of rate with progression tracked by area metrics. [Area of a circle= π (d/2)
2
]. With 
the simultaneous use of both EZW and EZA metrics we are thus able to prove this 




Arguably the exponential rates calculated may, in general, be more reflective of the average 
decline present in the population. Nonetheless phenotypic heterogeneity is evident in this 




There is a good level of interocular symmetry at baseline, with an RID of 3% for both EZW 
and EZA metrics. When characterizing progression, greater interocular symmetry was found 
with the use of EZW over the use of EZA metrics. RID for EZW rates was 1.54% compared to 
8.93% for EZA rates.  
 
Nevertheless, there was significant variation in the degree of interocular symmetry seen 
across the cohort, as typified by the RIV. RIV at baseline was 17.6% and 31.9% respectively 
for EZA and EZW metrics. RIV for progression rates were 78.0 % and 102.6% for EZA and 
EZW respectively.  
 
Despite this level of variation described, interocular correlation at baseline as assessed with 
both metrics were very strong (r ≥ 0.94, p<0.0001). Interocular correlation for progression 
as characterized by EZA (r= 0.93, p<0.0001) and EZW (r= 0.65, p= 0.0002) were also strong 
and significant. In addition, interocular differences at baseline and for progression rates 














This highlights the inadequacies of using correlation analyses as a sole method for assessing 
interocular symmetry. 
 
As an example, the mean baseline EZW in our cohort was 1964 µm. Despite a small mean 
interocular difference of 64 µm, the 95% LOA reached 669 µm. Thus, the implication is that 
observations are necessary for all subjects before inferring the presence of good interocular 
symmetry. As such, one can argue that in-depth natural history studies are a requirement 
prior to treatment trials for many reasons, including this.  
 
Test-retest Variability 
The 15% test-retest variability for EZW is comparable, albeit marginally smaller than the 
17% test-retest variability found with EZA-ART12. In comparison, test-retest variability was 
28% for EZA measurements derived from volume scans acquired without averaging. This 
finding indicates that both EZW and EZA-ART12 measurements are metrics with similar 
precision. Test-retest variability for both EZW and EZA-ART12 are equivalent to 
corresponding annual progression rates of 13% and 17% respectively.  
 
The greater precision seen with EZW and EZA-ART12 measurements is not unexpected. EZW 
measurements were made on transfoveal lines scans acquired with an average of 100 
images each, thus rendering a high signal to noise ratio. This high average number of images 
is achievable as only one line scan is obtained per transfoveal image. 
 
Following procurement of the Spectralis OCT2 module (Heidelberg Engineering), the 
significant reduction in acquisition time allowed high-resolution volume scans to be 
obtained with an average of 12 images per b-scan while maintaining the 193 b-scan density 
of each scan. EZA borders were more clearly visible on en face images generated from these 
ART12 volume scans (Figure 2), thus allowing for greater precision and better measurement 
repeatability, in contrast to EZA measurements made on images generated from earlier 
volume scans acquired without averaging.  
 
Test-retest Variability Reported in Other Studies 
None of the aforementioned studies assessed observer repeatability in XLRP subjects 
despite studying XLRP cohorts. One study selected 13 subjects with ADRP (from 59 subjects 
including 26 with XLRP) with images measured twice over an unspecified time interval. Their 
intra-observer test-retest variability was estimated at 7.3% with a repeatability coefficient 
of 0.9 degrees (260 µm) and mean baseline EZW of 12.4 degrees (3584 µm). Mean annual 
constriction rate for their adRP cohort was 3.4%, indicating their test-retest variability was 




Two related studies 
14,15
 assessed repeatability in image acquisition but not image 
measurement. In both studies, a different group of RP patients (AR or simplex RP) to those 
reported were imaged twice on the same day. Another study whose cohort comprised of RP 
of mixed inheritances assessed intra-observer repeatability with images measured twice 
several weeks apart, and reported a repeatability coefficient of 233 µm with test-retest 



















Comparisons of Test-retest Variability with Indices of Interocular Symmetry 
The mean of intra-observer test-retest difference is small in comparison to the mean of 
interocular difference for both metrics. For EZW, mean of intra-observer test-retest 
difference is 21.3 µm compared to 63.5 µm for mean of interocular difference. For EZA 
metric, mean intra-observer test-retest difference is 0.03 mm
2
, in comparison to 0.10 mm
2
 
for mean of interocular difference. Thus, both metrics are suitable for use as structural OCT 
measures to quantify disease.  
 
The 95% LOA for interocular symmetry with the EZW metric was -542 µm to 669 µm. In 
comparison, corresponding 95% LOA for test-retest repeatability was -316 µm to 273 µm. 
Likewise, test-retest repeatability coefficient of 294 µm for EZW is less than half its 
corresponding interocular coefficient of 605 µm. This finding of a test-retest repeatability 
that is under half that of expected interocular symmetry values further indicates that the 
EZW metric is reliable for use, especially where quantification of disease in the fellow eye is 
important, for example in cases where the fellow eye would be expected to act as a control 
to the eye undergoing the treatment trial.  
 
With regards to the EZA metric, the 95% LOA for interocular symmetry of -0.49 mm
2





is approximately similar to the corresponding 95% LOA for test-retest repeatability of -
0.73 mm
2
 to 0.57 mm
2 
obtained with EZA-ART12. Test-retest repeatability coefficient of 0.65 
mm
2
 is also approximately similar to the corresponding interocular coefficient of 0.59 mm
2
. 
These findings again indicate that the EZA is a suitable metric for use particularly when 
measurements are derived from dense volume scans obtained with good image averaging 
protocols.  
 
The 95% LOA for EZA test-retest repeatability performed on scans acquired without 
averaging was larger at -1.06 mm
2
 to 1.01 mm
2
. As mentioned, EZA measurements were not 
as precise when made on en face images derived from volume scans acquired without 
averaging on the OCT1 during the initial period of the study. Nevertheless, these earlier EZA 
findings are of value and can play an important role as a secondary OCT metric to 
corroborate and confirm findings made with the EZW metric. 
 
Associations and Effects of Age on Baseline and Progression Rates  
We found a strong negative correlation between age and baseline, indicating that the EZ is 
smaller in older eyes. The moderate to strong negative correlation found between age and 
progression rates, together with the strong positive correlation between baseline and 
progression indicates that in general, progression is greater in younger eyes possessing a 
larger baseline.  
 
Results from the ANOVA (Table 4) further demonstrate the significant effects of age on 
baseline and progression rates. The largest baseline values and progression rates are seen in 
the youngest subjects of the cohort. Post-hoc comparisons confirm the biggest differences 
in baseline and rates were between subjects in younger age categories (Categories 1 and 2) 
compared to those in the older age categories (Categories 4 and 5). In contrast, the effects 
of mutation on baseline and progression were insignificant. Our current findings 

















Correlation of Structure and Function  
We have demonstrated good functional correlation with the use of both EZW and EZA as 
structural metrics. Correlations between EZW and functional metrics were stronger overall, 
however functional correlations with EZA were also significant. These findings provide 
further support for the use of both structural metrics as surrogate markers of disease in 
RPGR-RP; with the demonstrated functional correlation being of key importance to both 
patients and regulators alike.  
 
In conclusion, we have provided and discussed prospectively acquired SD-OCT data in a 
cohort of subjects with RPGR-RP with a particular focus on the EZ as a structural biomarker 
of disease. The use of two distinct EZ metrics together in conjunction adds to the robustness 
of this study. Both EZW and EZA metrics provide sensitive and complementary parameters 
to characterize structure and progression in the condition. We anticipate our natural history 
findings to inform recently commenced RPGR treatment trials, both in the recruitment of 
trial subjects as well as in adjudicating treatment response. Our findings will also be of use 
to clinicians caring for patients with RPGR-RP and other researchers in the expanding field of 
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Figure Captions  
 
Figure 1 shows horizontal transfoveal spectral domain optical coherence tomography scans 
of both eyes of a subject with RPGR-associated retinopathy. Vertical arrows mark the extent 
of the ellipzoid zone (EZ) on the scans. Ellipzoid zone width (EZW) was 7163 µm in the left 
eye (shown in top image) and 1534 µm in the right eye (shown in bottom image). Note that 
the large interocular difference found in this subject is not in keeping with the cohort.  
 
Figure 2 is a composite of four images. Top row images show en face images of the ellipzoid 
zone area (EZA) generated from high resolution macular volume scans of two subjects with 
RPGR-associated retinopathy. Bottom row images show delineation and quantification of 
respective EZAs from the same top row images. Images on the right column were generated 
from a macular volume scan acquired with an average of 12 images per b-scan.  
 
Figure 3 shows a Bland Altman plot illustrating interocular differences in ellipzoid zone 
width (EZW) at baseline. Interocular difference for each individual is plotted on the y-axis 
against the mean EZW value of both eyes. (Horizontal long dash line refers to the mean of 
interocular differences; horizontal dotted lines denote 95% limits of agreement). 
 
Figure 4 shows linear trend lines indicating progression, plotted from observations of 
ellipzoid zone width. Each line represents the right eye of a subject. Data from twenty-eight 
subjects who underwent three or more observations over an interval greater than one year 















Figure 5 shows scatterplots of ellipzoid zone width and ellipzoid zone area respectively, both 
plotted against subjects’ age. An exponential decline is evident for both. The reader is 
directed to Table 5 for further information on exponential decline rates calculated with the 







































Left Eyes Both 
Eyes 
Mean ± SD of 
intra-observer 
difference  
(µm for EZW/ 
mm
2 
for EZA)  
 


















95% LOA  



































12.38  17.12 14.99 29.82  26.93  28.03 13.38 19.55 17.48 
 
 
Table 1 shows intra-observer repeatability analysis of EZW and EZA measurements. Test-
retest measurements were performed a minimum of one week apart on 76 eyes of 38 
subjects for the EZW metric; 62 eyes of 31 subjects for the EZA metric; and 53 eyes of 27 
subjects for EZA-ART12. Repeatability coefficient = 1.96 (SD).  
 
EZW= ellipzoid zone width; EZA= ellipzoid zone area; ART12 = automatic real-time tracking 




























Indices of Interocular Symmetry 
 
Mean (SD)  95% CI  Mean (SD) 
 
95% CI  Mean (SD) 95% CI 
 


























 1461.28 to 
2545.51 














2.13 to 5.25 3.37 (5.60) 1.31 to 5.42 4.01 (6.72) 1.55 to 6.48 0.10 (0.30) -0.49 to 
0.70 




















































































































Table above describes baseline values and progression rates for EZW and EZA, together with 
respective indices of interocular symmetry. The number of eyes in the cohort for 
characterization of baseline EZW were 76 eyes of 38 subjects; baseline EZA with 62 eyes of 
31 subjects; EZW rate with 56 eyes of 28 subjects; EZA rate with 42 eyes of 21 subjects. 
Positive progression rates indicate constriction occurring over time. 
 
(EZW= ellipzoid zone width; EZA= ellipzoid zone area; SD= standard deviation; LOA= limits of 



































































Age with baseline  
 









































































Table above shows associations at baseline, progression and with age. Significance level 
alpha was set at 0.025 following Bonferroni correction for simultaneous analysis with two 
metrics (EZW and EZA). 
 




















Mean ± SD  
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Mean ± SD 
(no. of eyes) 
 
Age Categories  
 



































































Category 1 vs 
Categories 4,5 
(p<0.0001 for all); 
Category 2 vs 
Categories 4,5 
(p<0.0001); 






































Category 1 vs 
Categories 4,5 
(p<0.0001 for 
all); Category 1 
vs 3 (p= 0.0002); 
Category 2 vs 
Category 4 (p= 
0.0029); 
Category 2 vs 





































Category 1 vs 
Category 5 
(p=0.0007); 
Category 1 vs 
Category 4 
(p=0.0224); 
Category 2 vs 
Category 5 
(p=0.0019); 






































Category 1 vs 
Categories 4,5 
(p<0.0001); 
Category 2 vs 4 
(p= 0.0059); 
Category 2 vs 
Category 5 (p= 
0.0050) 













Mutation Function  
 



























































































Age and Mutation 
Function interaction 
 

























Table above shows the results of a 2-way ANOVA investigating the effects of age and 
mutation function on baseline values and progression rates, as characterized by EZW and 
EZA. Significance level alpha was set at 0.025 following Bonferroni correction. Post-hoc 
multiple pairwise comparisons between the age categories were performed using Tukey’s 
test with those reaching statistical significance shown. (Age categories: 1 = <10 years of age, 
2 = 10 to < 15 years, 3 = 15 to < 20 years, 4 = 20 to < 25 years, 5 = ≥ 25 years).  
 


















Slope (95% CI);  
p-value 
 
Annual % Exponential 
Decline Rate (95% CI)  
 
 





-0.0857 (-0.1024 to -0.0691); 
p<0.0001 
 































Table above shows overall progression modelled from EZW and EZA data. Annual 
exponential decline rates together with half-lives were calculated from slope values 
obtained using the mixed-models method with age designated as a fixed effects variable. All 
values were converted into natural log form prior to analyses in order to model an 
exponential decline. Half-lives with 95% confidence intervals were calculated with the 
equation t1/2 = - loge (2)/k. The significance of age exerting an effect on the model is 
denoted by the corresponding p-values. Significance level alpha was set at 0.025.  
 

















































































Table 6 above shows associations of structure and function at baseline. Significance level 
alpha was set at 0.025 following Bonferroni correction for simultaneous analysis with two 
structural metrics, EZW and EZA. Associations between EZW and BCVA/CS were studied on 
76 eyes of 38 subjects. Associations between EZW and MS/VTotal/V30 were studied on 53 
eyes of 28 subjects (28 right and 25 left eyes). Associations between EZA and BCVA/CS were 
studied on 62 eyes of 31 subjects. Associations between EZA and MS/VTotal/V30 were studied 
on 44 eyes of 23 subjects (23 right and 21 left eyes).  
 
 
EZW = ellipzoid zone width, EZA = ellipzoid zone area, BCVA = best corrected visual acuity 
recorded in logMAR units; CS = contrast sensitivity, MS = mean sensitivity. VTotal and V30 are 
volumetric metrics that characterize the total amount of sensitivity in the hill-of-vision as 
defined by the entire test grid (VTotal) or that contained within a central circle of 30˚ radius 
(V30). 
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